CSL Ltd Annual Report 2021

Retain and Grow Plan (RGP) Executive Performance and Alignment Plan (EPA) Non-Executive Director Plan (NED) Global Employee Share Plan (GESP) Total Number Weighted average exercise price Number Weighted average exercise price Number Weighted average exercise price Number Weighted average exercise price Number 717,104 A$0.00 433,523 A$0.00 1,748 A$0.00 96,508 A$243.95 1,768,433 415,189 A$0.00 167,045 A$0.00 2,228 A$0.00 192,553 A$228.62 777,015 (253,126) A$0.00 (138,369) A$0.00 (2,278) A$0.00 (179,960) A$236.94 (1,079,565) (3) A$0.00 (120) A$0.00 0 A$0.00 0 A$0.00 (1,936) (77,798) A$0.00 (35,958) A$0.00 (365) A$0.00 0 A$0.00 (117,676) 0 A$0.00 0 A$0.00 0 A$0.00 (9,889) A$243.95 (9,889) 801,366 A$0.00 426,121 A$0.00 1,333 A$0.00 99,212 A$229.74 1,336,382 0 A$0.00 0 A$0.00 492 A$0.00 0 A$0.00 8,842 Our Future Note 6: Research and Development The Group conducts research and development activities to support future development of products to serve our patient communities, to enhance our existing products and to develop new therapies. All costs associated with our research and development activities are expensed as incurred as uncertainty exists up until the point of regulatory approval as to whether a research and development project will be successful. At the point of approval, the total cost of development has largely been incurred. Development costs incurred after regulatory approval are expensed unless it meets the criteria to be recognised as intangible assets. The Group also gains control of Intellectual Property (IP) through acquisitions or licence arrangements. In certain circumstances the acquired IP will be capitalised, dependant on the phase of development. For the year ended 30 June 2021, the research and development costs, net of recoveries, were $1,001.4m (2020: $921.8m). Further information about the Group’s research and development activities can be found on the CSL website. CSL Limited Annual Report 2020/21 121